Interestingly, the multidrug-resistant cell line NCI/ADR-RES, resistant to adriamycin and other P-glycoprotein substrates, was less sensitive to GSI1 than the other breast cancer cell lines tested and than most other cancer cell lines. This evidence concerns the gene ABCB1 and breast carcinoma.